Restricted accessReview articleFirst published online 2023-6
A Systematic Review and Narrative Synthesis of Interventions to Address Substance Use Disorders and Other Mental Health Disorders in Prison Settings With a Focus on Low- and Middle-Income Countries
Interventions to treat substance use disorders (SUDs) and other mental health disorders (MHDs) in prison settings vary in both availability and effectiveness across contexts. Furthermore, incomplete characterization of intervention efficacy and/or effectiveness impacts the ability to know whether an intervention with demonstrated effectiveness in one setting will be effective in another setting. We systematically reviewed the literature for studies of interventions for SUDs and other MHDs conducted in prison settings, and synthesized the identified interventions and identified evidence gaps. Search strategies yielded 9,599 articles published between January 1, 2010, and December 31, 2020. A total of 82 articles were identified as eligible with interventions presented for SUDs (n = 52), for MHDs (n = 23), and for SUDs/MHDs (n = 7). Findings point to a narrow range of interventions of demonstrated effectiveness and to important gaps in the evidence-base for which high-quality research, particularly in low- and middle-income settings, is needed.
BainganaF.al’AbsiM.BeckerA. E.PringleB. (2015). Global research challenges and opportunities for mental health and substance-use disorders. Nature, 527(7578), S172–S177.
2.
BaranyiG.SchollC.FazelS.PatelV.PriebeS.MundtA. P. (2019). Severe mental illness and substance use disorders in prisoners in low-income and middle-income countries: A systematic review and meta-analysis of prevalence studies. Lancet Global Health, 7(4), e461–e471.
3.
BarrengerS. L.KriegelL. S.AngellB.DraineJ. (2016). Role of context, resources, and target population in the fidelity of critical time intervention. Psychiatric Services, 67(1), 115–118.
4.
BeaudryG.YuR.PerryA. E.FazelS. (2021). Effectiveness of psychological interventions in prison to reduce recidivism: A systematic review and meta-analysis of randomised controlled trials. Lancet Psychiatry, 8(9), 759–773.
5.
BirdS. M.FischbacherC. M.GrahamL.FraserA. (2015). Impact of opioid substitution therapy for Scotland’s prisoners on drug-related deaths soon after prisoner release. Addiction, 110(10), 1617–1624.
6.
BoesenK.JørgensenK. J.GøtzscheP. C. (2022). Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: A case study of public documents: Author’s reply. Journal of Clinical Epidemiology, 145, 183–184.
7.
Brinkley-RubinsteinL.McKenzieM.MacmaduA.LarneyS.ZallerN.DauriaE.RichJ. (2018). A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: Findings at 12 months postrelease. Drug and Alcohol Dependence, 184, 57–63.
8.
CarterH.ArayaR.AnjurK.DengD.NaslundJ. A. (2021). The emergence of digital mental health in low-income and middle-income countries: A review of recent advances and implications for the treatment and prevention of mental disorders. Journal of Psychiatric Research, 133, 223–246.
9.
ChangZ.LichtensteinP.LarssonH.FazelS. (2015). Substance use disorders, psychiatric disorders, and mortality after release from prison: A nationwide longitudinal cohort study. Lancet Psychiatry, 2(5), 422–430.
10.
ChapleM.SacksS.McKendrickK.MarschL.BelenkoS.LeukefeldC.PrendergastM.FrenchM. (2014). Feasibility of a computerized intervention for offenders with substance use disorders: A research note. Journal of Experimental Criminology, 10(1), 105–127.
11.
CusackK. J.MorrisseyJ. P.CuddebackG. S.PrinsA.WilliamsD. M. (2010). Criminal justice involvement, behavioral health service use, and costs of forensic assertive community treatment: A randomized trial. Community Mental Health Journal, 46(4), 356–363.
12.
DeanC. E. (2017). Social inequality, scientific inequality, and the future of mental illness. Philosophy, Ethics, and Humanities in Medicine, 12(1), Article 10.
13.
DegenhardtL.CharlsonF.StanawayJ.LarneyS.AlexanderL. T.HickmanM.CowieB.HallW. D.StrangJ.WhitefordH.VosT. (2016). Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: Findings from the Global Burden of Disease Study 2013. Lancet Infectious Disease, 16(12), 1385–1398.
14.
DegenhardtL.GlantzM.Evans-LackoS.SadikovaE.SampsonN.ThornicroftG.Aguilar-GaxiolaS.Al-HamzawiA.AlonsoJ.Helena AndradeL. (2017). Estimating treatment coverage for people with substance use disorders: An analysis of data from the World Mental Health Surveys. World Psychiatry, 16(3), 299–307.
15.
DegenhardtL.LarneyS.KimberJ.GisevN.FarrellM.DobbinsT.WeatherburnD. J.GibsonA.MattickR.ButlerT.BurnsL. (2014). The impact of opioid substitution therapy on mortality post-release from prison: Retrospective data linkage study. Addiction, 109(8), 1306–1317.
16.
DhandaA.SalsitzE. A. (2021). The duration dilemma in opioid agonist therapy. Journal of Opioid Management, 17(4), 353–358.
17.
DimitrisM. C.GittingsM.KingN. B. (2021). How global is global health research? A large-scale analysis of trends in authorship. BMJ Global Health, 6(1), Article e003758.
18.
DolanK. A.ShearerJ.WhiteB.ZhouJ.KaldorJ.WodakA. D. (2005). Four-year follow-up of imprisoned male heroin users and methadone treatment: Mortality, re-incarceration and hepatitis C infection. Addiction, 100(6), 820–828.
FarabeeD.CondonT.HallgrenK. A.McCradyB. (2020). A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder. Journal of Substance Abuse Treatment, 117, Article 108076.
21.
FluyauD.RevadigarN.PierreC. G. (2021). Systematic review and meta-analysis: Treatment of substance Use disorder in attention deficit hyperactivity disorder. American Journal of Addictions, 30(2), 110–121.
22.
ForsbergL. G.ErnstD.SundqvistK.FarbringC. (2011). Motivational Interviewing delivered by existing prison staff: A randomized controlled study of effectiveness on substance use after release. Substance Use and Misuse, 46(12), 1477–1485.
23.
Garcia-GuerreroJ.MarcoA. (2012). Overcrowding in prisons and its impact on health. Revista Espanola de Sanidad Penitenciaria, 14(3), 106–113.
24.
GinsbergY.HirvikoskiT.GrannM.LindeforsN. (2012). Long-term functional outcome in adult prison inmates with ADHD receiving OROS-methylphenidate. European Archives of Psychiatry and Clinical Neuroscience, 262(8), 705–724.
25.
GinsbergY.LangstromN.LarssonH.LindeforsN. (2015). Long-term treatment outcome in adult male prisoners with attention-deficit/hyperactivity disorder: Three-year naturalistic follow-up of a 52-week methylphenidate trial. Journal of Clinical Psychopharmacology, 35(5), 535–543.
26.
GolbersteinE.EisenbergD.GollustS. E. (2008). Perceived stigma and mental health care seeking. Psychiatric Services, 59(4), 392–399.
27.
GordonM. S.BlueT. R.CouvillionK.SchwartzR. P.GradyK. E.FitzgeraldT. T.VocciF. J. (2018). Initiating buprenorphine treatment prior to versus after release from prison: Arrest outcomes. Drug and Alcohol Dependence, 188, 232–238.
28.
GordonM. S.KinlockT. W.SchwartzR. P.GradyK. E.FitzgeraldT. T.VocciF. J. (2017). A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release. Drug and Alcohol Dependence, 172, 34–42.
29.
GrommonE.DavidsonW. S.BynumT. S. (2013). A randomized trial of a multimodal community-based prisoner reentry program emphasizing substance abuse treatment. Journal of Offender Rehabilitation, 52(4), 287–309.
30.
HechanovaM. M. M.ReyesJ. C.AcostaA. C.TuliaoA. P. (2020). Psychosocial treatment for incarcerated methamphetamine users: The Philippines experience. International Journal of Prisoner Health, 16(4), 343–358.
31.
Herrera RodríguezJ. (2014). Estudio del clima social y variables que lo influyen en un centro penitenciario femenil de aguascalientes, México. Revista Criminalidad, 56(3), 59–68.
32.
HidesL.QuinnC.StoyanovS.KavanaghD.BakerA. (2019). Psychological interventions for co-occurring depression and substance use disorders. Cochrane Database of Systematic Reviews, 11, Article CD009501.
33.
HigginsJ. P. (2008). Cochrane handbook for systematic reviews of interventions (Version 5.0.1). The Cochrane Collaboration.
34.
JacobK. S.SharanP.MirzaI.Garrido-CumbreraM.SeedatS.MariJ. J.SreenivasV.SaxenaS. (2007). Mental health systems in countries: Where are we now?The Lancet, 370(9592), 1061–1077.
35.
JaeschkeK.HannaF.AliS.ChowdharyN.DuaT.CharlsonF. (2021). Global estimates of service coverage for severe mental disorders: Findings from the WHO Mental Health Atlas 2017. Global Mental Health, 8, Article e27.
36.
JalaliF.HashemiS. F.HasaniA.Fakoor SharghiN. (2017). The effectiveness of cognitive group therapy based on schema-focused approach on self-esteem and emotion regulation in drug addicted prisoners under the methadone maintenance treatment (MMT). Journal of Groups in Addiction & Recovery, 12(4), 284–295.
37.
JarrettM.ThornicroftG.ForresterA.HartyM.SeniorJ.KingC.HuckleS.ParrottJ.DunnG.ShawJ. (2012). Continuity of care for recently released prisoners with mental illness: A pilot randomised controlled trial testing the feasibility of a Critical Time Intervention. Epidemiology and Psychiatric Sciences, 21(2), 187–193.
38.
JordanA. E.ClelandC. M.WykaK.SchackmanB. R.PerlmanD. C.NashD. (2020). Hepatitis C virus incidence in a cohort in medication-assisted treatment for opioid use disorder in New York City. Journal of Infectious Diseases, 222(S5), S322–S334.
39.
JordanA. E.PerlmanD. C.SmithD. J.ReedJ. R.HaganH. (2018). Use of the PRECIS-II instrument to categorize reports along the efficacy-effectiveness spectrum in an hepatitis C virus care continuum systematic review and meta-analysis. Journal of Clinical Epidemiology, 93, 66–75.
40.
KellyS. M.SchwartzR. P.O’GradyK. E.MitchellS. G.DurenT.SharmaA.JaffeJ. H. (2020). Impact of methadone treatment initiated in jail on subsequent arrest. Journal of Substance Abuse Treatment, 113, Article 108006.
41.
KhanS. A. (2022). Decolonising global health by decolonising academic publishing. BMJ Global Health, 7(3), Article e007811.
42.
KohrtB. A.AsherL.BhardwajA.FazelM.JordansM. J. D.MutambaB. B.NadkarniA.PedersenG. A.SinglaD. R.PatelV. (2018). The role of communities in mental health care in low- and middle-income countries: A meta-review of components and competencies. International Journal of Environmental Research and Public Health, 15(6), Article 1279.
43.
KonsteniusM.Jayaram-LindströmN.GuterstamJ.BeckO.PhilipsB.FranckJ. (2014). Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: A 24-week randomized placebo-controlled trial. Addiction, 109(3), 440–449.
44.
KubiakS. P.KimW. J.FedockG.BybeeD. (2015). Testing a violence-prevention intervention for incarcerated women using a randomized control trial. Research on Social Work Practice, 25(3), 334–348.
45.
LambertiJ. S.WeismanR. L.CerulliC.WilliamsG. C.JacobowitzD. B.MueserK. T.MarksP. D.StrawdermanR. L.HarringtonD.LambertiT. A.CaineE. D. (2017). A randomized controlled trial of the Rochester Forensic Assertive Community Treatment Model. Psychiatric Services, 68(10), 1016–1024.
46.
LeeB. X.KjaerulfF.TurnerS.CohenL.DonnellyP. D.MuggahR.DavisR.RealiniA.KieselbachB.MacGregorL. S.WallerI.GordonR.Moloney-KittsM.LeeG.GilliganJ. (2016). Transforming our world: Implementing the 2030 agenda through Sustainable Development goal indicators. Journal of Public Health Policy, 37(S1), 13–31.
47.
LevinC.ChisholmD. (2016). Cost-effectiveness and affordability of interventions, policies, and platforms for the prevention and treatment of mental, neurological, and substance use disorders. In PatelV.ChisholmD.DuaT.LaxminarayanR.Medina-MoraM. E. (Eds.), Mental, neurological, and substance use disorders: Disease control priorities (3rd ed., Vol. 4, pp. 219–236). The International Bank for Reconstruction and Development, The World Bank.
48.
LynchS. M.DehartD. D.BelknapJ. E.GreenB. L.Dass-BrailsfordP.JohnsonK. A.WhalleyE. (2014). A multisite study of the prevalence of serious mental illness, PTSD, and substance use disorders of women in jail. Psychiatric Services, 65(5), 670–674.
49.
MageeL. A.FortenberryJ. D.RosenmanM.AalsmaM. C.GharbiS.WieheS. E. (2021). Two-year prevalence rates of mental health and substance use disorder diagnoses among repeat arrestees. Health Justice, 9(1), Article 2.
50.
MaltaM.VaratharajanT.RussellC.PangM.BonatoS.FischerB. (2019). Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review. PLOS Medicine, 16(12), Article e1003002.
51.
MartinM. S.ColmanI.SimpsonA. I.McKenzieK. (2013). Mental health screening tools in correctional institutions: A systematic review. BMC Psychiatry, 13, Article 275.
52.
McKenzieM.ZallerN.DickmanS. L.GreenT. C.ParihkA.FriedmannP. D.RichJ. D. (2012). A randomized trial of methadone initiation prior to release from incarceration. Substance Abuse, 33(1), 19–29.
53.
McLeodK. E.ButlerA.YoungJ. T.SouthalanL.BorschmannR.Sturup-ToftS.DirkzwagerA.DolanK.AcheampongL. K.ToppS. M.MartinR. E.KinnerS. A. (2020). Global prison health care governance and health equity: A critical lack of evidence. American Journal of Public Health, 110(3), 303–308.
54.
MoherD.ShamseerL.ClarkeM.GhersiD.LiberatiA.PetticrewM.ShekelleP.StewartL. A. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews, 4(1), Article 1.
55.
MooreK. E.RobertsW.ReidH. H.SmithK. M. Z.OberleitnerL. M. S.McKeeS. A. (2019). Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review. Journal of Substance Abuse Treatment, 99, 32–43.
56.
MundtA. P.BaranyiG.GabryschC.FazelS. (2018). Substance use during imprisonment in low- and middle-income countries. Epidemiologic Reviews, 40(1), 70–81.
57.
NathanR.CentifantiL.BakerV.HillJ. (2019). A pilot randomised controlled trial of a programme of psychosocial interventions (Resettle) for high risk personality disordered offenders. International Journal of Law Psychiatry, 66, Article 101463.
58.
NordonC.KarcherH.GroenwoldR. H.AnkarfeldtM. Z.PichlerF.Chevrou-SeveracH.RossignolM.AbbeA.AbenhaimL. (2016). The “efficacy-effectiveness gap”: Historical background and current conceptualization. Value Health, 19(1), 75–81.
59.
PapaliaN. L.LuebbersS.OgloffJ. R.CutajarM.MullenP. E. (2017). The long-term co-occurrence of psychiatric illness and behavioral problems following child sexual abuse. Australian & New Zealand Journal of Psychiatry, 51(6), 604–613.
60.
PardiniJ.ScoginF.SchriverJ.DominoM.WilsonD.LaRoccaM. (2014). Efficacy and process of cognitive bibliotherapy for the treatment of depression in jail and prison inmates. Psychological Services, 11(2), 141–152.
61.
PatelV.ChisholmD.ParikhR.CharlsonF. J.DegenhardtL.DuaT.FerrariA. J.HymanS.LaxminarayanR.LevinC.LundC.Medina MoraM. E.PetersenI.ScottJ.ShidhayeR.VijayakumarL.ThornicroftG.WhitefordH. (2016). Addressing the burden of mental, neurological, and substance use disorders: Key messages from Disease Control Priorities, 3rd edition. The Lancet, 387(10028), 1672–1685.
62.
PerlmanD. C.JordanA. E. (2018). The syndemic of opioid misuse, overdose, HCV, and HIV: Structural-level causes and interventions. Current HIV/AIDS Reports, 15(2), 96–112.
63.
PrendergastM.FrismanL.SacksJ. Y.Staton-TindallM.GreenwellL.LinH. J.CartierJ. (2011). A multi-site, randomized study of strengths-based case management with substance-abusing parolees. Journal of Experimental Criminology, 7(3), 225–253.
64.
RamezaniN.BrenoA. J.MackeyB. J.ViglioneJ.CuellarA. E.JohnsonJ. E.TaxmanF. S. (2022). The relationship between community public health, behavioral health service accessibility, and mass incarceration. BMC Health Services Research, 22(1), Article 966.
65.
RojasE. C.PetersR. H. (2016). Evidence-based practices for co-occurring disorders in offenders. Addiction Research & Theory, 24(3), 223–235.
66.
SacksS.ChapleM.SacksJ. Y.McKendrickK.ClelandC. M. (2012). Randomized trial of a reentry modified therapeutic community for offenders with co-occurring disorders: Crime outcomes. Journal of Substance Abuse Treatment, 42(3), 247–259.
67.
SanderG.Shirley-BeavanS.StoneK. (2019). The global state of harm reduction in prisons. Journal of Correctional Health, 25(2), 105–120.
68.
ScottC. K.DennisM. L.LurigioA. J. (2017). The effects of specialized probation and recovery management checkups (RMCs) on treatment participation, substance use, HIV risk behaviors, and recidivism among female offenders: Main findings of a 3-year experiment using subject by intervention interaction analysis. Journal of Experimental Criminology, 13(1), 53–77.
69.
SingalA. G.HigginsP. D.WaljeeA. K. (2014). A primer on effectiveness and efficacy trials. Clinical and Translational Gastroenterology, 5(1), Article e45.
70.
StewartL. A.Farrell-MacDonaldS.FeeleyS. (2017). The impact of a community mental health initiative on outcomes for offenders with a serious mental disorder. Criminal Behaviour and Mental Health, 27(4), 371–384.
SurekaP.GovilS.DashD.DashC.KumarM.SinghalV. (2014). Effect of Sudarshan Kriya on male prisoners with non psychotic psychiatric disorders: A randomized control trial. Asian Journal of Psychiatry, 12, 43–49.
73.
TurnerM. W.BogdewicS.AghaE.BlanchardC.SturkeR.PettiforA.SalisburyK.MarquesA. H.ExcellentM. L.RajagopalN.RamaswamyR. (2021). Learning needs assessment for multi-stakeholder implementation science training in LMIC settings: Findings and recommendations. Implementation Science Communications, 2(1), Article 134.
VafamandE.KargarfardM.MarandiM. (2012). Effects of an eight-week aerobic exercise program on dopamine and serotonin levels in addicted women in the central prison of Isfahan, Iran. Journal of Isfahan Medical School, 30(204), 1336–1347 (in Persian).
78.
Van Den BergC.SmitC.Van BrusselG.CoutinhoR.PrinsM. (2007). Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: Evidence from the Amsterdam Cohort Studies among drug users. Addiction, 102(9), 1454–1462.
79.
Villagra LanzaP.Fernandez GarcíaP.Rodgriguez LamelasF.González-MenéndezA. (2014). Acceptance and Commitment Therapy versus cognitive behavioral therapy in the treatment of substance use disorder with incarcerated women. Journal of Clinical Psychology, 70(7), 644–657.
80.
WangP. S.Aguilar-GaxiolaS.AlonsoJ.AngermeyerM. C.BorgesG.BrometE. J.BruffaertsR.De GirolamoG.De GraafR.GurejeO. (2007). Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys. The Lancet, 370(9590), 841–850.
81.
WesterbergV. S.McCradyB. S.OwensM.GuerinP. (2016). Community-based methadone maintenance in a large detention center is associated with decreases in inmate recidivism. Journal of Substance Abuse Treatment, 70, 1–6.
World Health Organization. (2016). mhGAP intervention guide for mental, neurological and substance use disorders in non-specialized health settings: Mental health gap action programme (mhGAP): Version 2.0. https://www.who.int/publications/i/item/9789241549790
World Health Organization and United Nations Office on Drugs and Crime. (2020). International standards for the treatment of drug use disorders: Revised edition incorporating results of field-testing. https://apps.who.int/iris/handle/10665/331635
86.
YoonI. A.SladeK.FazelS. (2017). Outcomes of psychological therapies for prisoners with mental health problems: A systematic review and meta-analysis. Journal of Consulting and Clinical Psychology, 85(8), 783–802.
87.
ZielinskiM. J.AllisonM. K.Brinkley-RubinsteinL.CurranG.ZallerN. D.KirchnerJ. A. E. (2020). Making change happen in criminal justice settings: Leveraging implementation science to improve mental health care. Health Justice, 8(1), Article 21.
88.
ZiemannA.BrownL.SadlerE.OclooJ.BoazA.SandallJ. (2019). Influence of external contextual factors on the implementation of health and social care interventions into practice within or across countries-a protocol for a “best fit” framework synthesis. Systematic Reviews, 8(1), Article 258.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
